Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Acute Leukoencephalopathies:Differential Diagnosis and Investigation
The Neurologist 4:148-166, Weinshenker,B.G.,et al, 1998
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Radiologically Isolated Syndrome: A Review for Neuroradiologists
AJNR 41:1542-1549, Hosseiny, M.,et al, 2020
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Responsibilities of Health Care PRofessionals in Counseling and Educating Patients with Incurable Neurological Diseases Regarding "Stem Cell Tourism"
JAMA Neurol 72:1342-1345, Bowman, M.,et al, 2015
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Should Doctors Prescribe Cannabinoids?
BMJ 348:g2737, Farrell, M.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014
Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012
Immune Reconstitution Inflammatory Syndrome in Natalizumab-Associated PML
Neurol 77:1061-1067,1033, Tan, I.L.,et al, 2011
Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types
AJNR 31:541-548, 390, Vrenken,H.,et al, 2010
Clinicopath Conf, Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
NEJM 360:1656-1665, Case 12-2009, 2009
Diffusely Abnormal White Matter in Chronic Multiple Sclerosis: Imaging and Histopathologic Analysis
Arch Neurol 66:601-609, Seewann,A.,et al, 2009
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
Gray and White Matter Brain Atrophy and Neuropsychological Impairment in Multiple Sclerosis
Neurol 66:685-692, Sanfilipo,M.P.,et al, 2006
Migraine and Cerebral White Matter Lesions
The Neurologist 11:19-29, Gladstone,J.P. &Dodick,D.W., 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
NEJM 353:369-374,414,432, Kleinschemidt-DeMasters,B.K. &Tyler,K.L., 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Multiple Sclerosis Presenting as Lower Motor Neuron Wasting and Weakness of the Distal Upper Extremity
Neurol 61:1303-1304, Chong,P.S.T.,et al, 2003
Dirty-Appearing White Matter in Multiple Sclerosis: Volumetric MR Imaging and Magnetization Transfer Ratio Histogram Analysis
AJNR 24:1935-1940,1929, Ge,Y.,et al, 2003
Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
De Novo Mutation in the Notch3 Gene Causing CADASIL
Ann Neurol 47:388-391, Joutel,A.,et al, 2000
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
A 29-Year-Old Man with Multiple Sclerosis
JAMA 280:1432-1439, Rudick,R.A., 1998
Tizanidine for Spasticity
The Medical Letter 39:62, , 1997
Management of Patients Receiving Interferon Beta-1b for MS:Report of a Consensus Conf
Neurol 46:12-18, Lublin,F.D.,et al, 1996
Palliative Care in Neurology
Neurol 46:870-872, 5981996., Bernat,J.L.,et al, 1996
Is Chronic Respiratory Failure in Neuromuscular Diseases Worth Treating
JNNP 61:1-3, Shneerson,J.M., 1996
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
Tizanidine Treatment of Spasticity Caused by Multiple Sclerosis:Results of a Double-Blinded, Placebo-Controlled Trial
Neurol 44:S34-S43, Smith,C.,et al, 1994
A Double-Blind, Placebo-Controlled Trial of Tizanidine in the Treatment of Spasticity Caused by Multiple Sclerosis
Neurol 44:S70-S78, Barnes,M.P.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Surgical Treatment of Cervical Spondylotic Myelopathy:Time for a Controlled Trial
Neurol 42:5-13, Rowland,L.P., 1992
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Peripheral Nervous System Involvement in Multiple Sclerosis
Neurol 41:457-460, Zee,P.C.,et al, 1991
A Case of Myelinoclastic Diffuse Sclerosis in an Adult
Neurol 41:316-318, Dresser,L.P.,et al, 1991
Neuromuscular Blockade
Lancet 335:382-384, , 1990
Acute Disseminated Encephalomyelitis, MRI Findings & the Distinction from Multiple Sclerosis
Brain 113:291-302, Kesselring,J.,et al, 1990